CollPlant Biotechnologies (CLGN) Accumulated Expenses (2018 - 2026)

CollPlant Biotechnologies has reported Accumulated Expenses for 9 years, with the latest figure at -$4000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 33.33% year-over-year to -$4000.0; the trailing twelve-month figure through Mar 2026 stood at -$4000.0 (down 33.33% YoY), and the FY2025 full-year result was -$15000.0, down 36.36% from the prior year.
• Accumulated Expenses for Q1 2026 stood at -$4000.0, up from -$15000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.5 million in Q1 2023, with the low at -$87000.0 in Q4 2022.
• Historically, Accumulated Expenses has averaged $615437.5 across 5 years, with a median of $482000.0 in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 67.82% — and 2025, when it sank 100.79%.
• CollPlant Biotechnologies' Accumulated Expenses stood at -$87000.0 in 2022, then soared by 67.82% to -$28000.0 in 2023, then jumped by 60.71% to -$11000.0 in 2024, then sank by 36.36% to -$15000.0 in 2025, then soared by 73.33% to -$4000.0 in 2026.
• The last three Accumulated Expenses figures came in at -$4000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$10000.0 (Q3 2025), per Business Quant data.